



CORPATH SYSTEM TO BE HIGHLIGHTED AT 2016 CARDIOVASCULAR RESEARCH TECHNOLOGIES MEETING

Groundbreaking Masters in Transradial Intervention session and podium talks feature robotics for PCI and highlight the CorPath System

WALTHAM, MA – February 22, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that it will provide hands-on demonstrations of complex robotic-assisted [percutaneous coronary intervention](#) (PCI) using the CorPath® System at the 2016 [Cardiovascular Research Technologies](#) (CRT) meeting to be held in Washington, DC on February 20-23. CRT is a comprehensive interventional cardiology conference that attracts more than 2,000 interventional and cardiovascular specialists.

The CorPath System will be featured in several sessions:

- *"Robotic PCI: Practical Considerations for Adoption of Robotics in Your Cath Lab,"* a presentation by Dr. Robert Madder of Spectrum Health taking place on Tuesday, February 23 at 8:50 a.m.
- *"Robotically-assisted Peripheral Vascular Intervention,"** a presentation by Dr. Ehtisham Mahmud, Division Chief of Cardiovascular Medicine, Director of the Sulpizio Cardiovascular Center and Interventional Cardiology at UC San Diego taking place on Tuesday, February 23 at 9:00 a.m.
- Participation in the Masters Transradial Intervention Course, a first-of-its-kind course dedicated to bringing together industry leaders to discuss the advancements of radial access adoption in the U.S. Corindus is a sponsor of the event along with a small group of other industry leaders.

"I am excited about the partnership between Corindus and CRT," said Ron Waksman, MD, CRT 2016 Course Chairman. "I know first-hand about the benefits of the CorPath System, and count myself among the pioneers who brought this technology to MedStar Washington Hospital Center. It is important that physicians understand their need for protection in the cath lab, and that the CorPath System can be a solution to risks they face on a daily basis."

For the first time, the CRT conference features a special transradial intervention master's course. Radial access is widely considered the standard of care outside the U.S. and, while data has shown that it improves clinical outcomes by reducing PCI-related complications for the patient, it is also known to increase radiation exposure to the operator.

"Radiation exposure protection provided by the CorPath System becomes increasingly important as more physicians adopt radial access as a standard practice," said David Handler, President and CEO, Corindus. "We are excited to participate in the radial master's course and look forward to highlighting CorPath robotic-assisted PCI at CRT, a conference that brings the latest clinical research and technological advancements to the interventional community."

Attendees can participate in hands-on demonstrations of the CorPath System with an advanced simulator at CRT at Corindus Vascular Robotics Booth #103. For additional information, visit www.corindus.com, and follow @CorindusInc.

*The CorPath 200 System has not been cleared for use in Peripheral Vascular Interventions by the FDA. Corindus, Inc. sponsored the RAPID Trial.

About Corindus Vascular Robotics, Inc.

[Corindus Vascular Robotics, Inc.](http://www.corindus.com) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to PCI procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus' financial results is included from time to time in the "Forward Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward Looking Statements" section of Corindus' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus' website at <http://www.corindus.com/about-corindus/investor-relations>. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

###

Media Contacts:

Corindus Vascular Robotics
Brett Prince
(508) 653-3335 ext. 231
Brett.prince@corindus.com

Yuliya Kutuzava
(203) 504-8230 ext. 131
corindus@knbpr.com

Investor Contact:

Lynn Pieper Lewis
415-309-5999
ir@corindus.com